Witryna13 cze 2024 · 该研究是一项全球性,多中心,随机,对照研究,对比阿维鲁单抗联合阿昔替尼治疗组与舒尼替尼安慰剂组,用于晚期肾癌一线治疗的随机3期临床试验,初步结果显示PD-L1表达阳性患者联合治疗组可显著延长中位无进展生存期PFS与总生存期OS。 摘要4574更新了JAVELIN Renal 101研究第3次中期分析及不同IMDC危险分层中的疗效。 … Witryna25 lip 2024 · IMmotion010研究是一项随机、双盲、安慰剂对照的III期临床试验,旨在评估Tecentriq用于手术切除后高复发风险的肾细胞癌患者的辅助治疗的疗效。 此次失利 …
MNC临床失败众生相:辉瑞果断停III期,诺华潜在FIC眼药项目终 …
Witryna6 gru 2024 · IMmotion010 is an ongoing phase III placebo-controlled trial of atezolizumab given for 1 year as adjuvant therapy in RCC at high risk of metastasis following nephrectomy (NCT03024996) and will report in 2024. KEYNOTE 564 is a phase III, placebo-controlled trial to assess pembrolizumab after surgery given on 3-week … Witryna27 lip 2024 · This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy . How does the IMmotion010 clinical trial work? This clinical trial is recruiting people … shutterfly images
2024年制药巨头失败临床研究 替尼 单抗 帕博利珠 治疗 仑伐 单药_ …
Witryna18 wrz 2024 · IMMOTION 010是一项III期、多中心、随机、安慰剂对照、双盲试验,评估了阿替利珠单抗(抗PD-L1单抗)单药在肾切除术后疾病复发风险较高患者辅助治疗 … Witryna10 wrz 2024 · The data from the IMmotion010 trial suggest that atezolizumab has little effect after nephrectomy and that other factors have probably counterbalanced the risk of progression among patients enrolled in IMmotion010 and KEYNOTE-564. For instance, 84 (78%) of 108 patients with M1 no evidence of disease included in the … the paisley bride lewistown